UT Health San Antonio identifies the first potential probiotic treatment for lupus

June 26, 2026 - 04:20

Scientists at UT Health San Antonio have identified what could be the first probiotic treatment for lupus, a chronic autoimmune disease that affects millions of people worldwide. The discovery centers on a specific bacterium found in the gut microbiome, the complex ecosystem of microorganisms living in the digestive tract.

The research team found a direct link between this bacterium and the development of lupus symptoms. By studying the gut microbiome of patients with the disease, they noticed a significant imbalance in certain bacterial populations. When they introduced a specific strain of bacteria as a probiotic in laboratory models, they observed a reduction in inflammation and other markers associated with lupus.

Lupus occurs when the immune system mistakenly attacks healthy tissues, causing pain, swelling, and damage to organs such as the skin, kidneys, and heart. Current treatments often rely on broad immunosuppressants, which can leave patients vulnerable to infections and other side effects. A targeted probiotic therapy could offer a safer, more natural way to manage the disease by restoring balance to the gut ecosystem.

The team believes this approach could lead to a new class of treatments that work with the body's own biology rather than suppressing its immune response. While the findings are still in early stages, they represent a significant step forward in understanding how gut health influences autoimmune conditions.

Further studies are needed to confirm the results in human trials and to develop a viable probiotic supplement for patients. If successful, this could transform the standard of care for lupus and potentially other autoimmune disorders.